Screener
Veracyte VCYT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Decrease in cash, cash equivalents and restricted cash | (99,375) | (52,940) |
| Effect of foreign currency on cash, cash equivalents and restricted cash | (58) | 74 |
| Net decrease in cash, cash equivalents and restricted cash | (99,433) | (52,866) |
| Cash, cash equivalents and restricted cash at beginning of period | 364,226 | 240,631 |
| Cash, cash equivalents and restricted cash at end of period | $264,793 | $187,765 |
| Supplementary cash flow information: | ||
| Purchases of property, plant and equipment included in accounts payable and accrued liability | $2,317 | $977 |
| Cash paid for tax | $164 | $121 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's cash & equivalents?
- Veracyte (VCYT) reported cash & equivalents of $264.79M in Q1 2026.
- How has Veracyte's cash & equivalents changed year-over-year?
- Veracyte's cash & equivalents increased by 41.0% year-over-year, from $187.77M to $264.79M.
- What is the long-term trend for Veracyte's cash & equivalents?
- Over 5 years (2020 to 2025), Veracyte's cash & equivalents has grown at a 0.8% compound annual growth rate (CAGR), from $349.97M to $364.23M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Veracyte's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude